A blog about chemistry, drug development, science, and technology
Pages (999999): « First ... « 4 5 [6] 7 8 » ... Last »
I apologize for not posting for a while. I have recently taken a new job and have been busy trying to get podcasts set up for my church and for an organization I belong to. These have eaten up large portions of my time.
I do have a whole bunch of articles I hope to comment on soon. Stay tuned!
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
Replidyne is continuing to refine its phase III efforts for the antibiotic faropenem.
This new antibiotic may be the first to be approved under the FDA’s new community standards for antibiotics.
Technorati Tags: Faropenem, Replidyne
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
Seems the Sanofi BMS merger talks haven’t been without some truth to them. Now the Times Online is reporting that there is a split on the Sanofi side over strategy
The Times has learnt that a disagreement over strategy has emerged between Jean-François Dehecq, the Sanofi chairman, who favours a transformational deal with BMS, and Gérard Le Fur, his younger chief executive, who has emphasised the need to focus on the group’s internal drug research and development programme.
The article goes on to say that the former view of merger with transformation is more probable. I think that it might be the less attractive strategy in the long run. I’m not a big fan of mergers since few ever really show the advantages that are promised.
I think the continuing trend of mega-mergers in the pharmaceutical industry will continue but I also do not think it will solve the long terms problems of the industry.
Technorati Tags: BMS, Bristol-Myers Squibb, pharma M&A, pharmaceutical deals, Sanofi-Aventis
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
In get caught up on some reading, I came across this article from Pharmaceutical Manufacturing concerning drug safety.
I reported recently about drug safety and establishing database and this article has even more details. I highly recommend these two articles article. They were written by Dr. Henry I. Miller of the Hoover Institution. He is an ex-FDA who worked at the administration from 1979 until 1993 and was one of the founding directors of the Office of Biotechnology at the FDA where he served as head from 1989-1993. The first is about harmful side effects of drugs and the mismanagement at the FDA and the second deals legislation currently before Congress. I highly recommend both of these articles.
Technorati Tags: drug safety, FDA
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
I missed posting on this when I first saw it but thought folks might be interested in some new federal guidance for disposing of old or unused prescription medicines.
Proper Disposal of Prescription Drugs
The most important point is that you should NOT flush drugs down the toilet unless the accompanying direction specifically say to do so. Municipal waste water treatment plats are not set up to handle this and it can cause environmental problems. In general, the unused or old medication should be placed in the trash in nondescript containers.
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
Seems Representative Henry Waxman (D, CA) wants to hear from the following companies about the following drugs for the following reasons:
Lilly: Zyprexa (bipolar). Inappropriate promotion for off-label use
AstraZeneca: Seroquel (schizophrenia). Inappropriate marketing
Boston Scientific: drug coated stents. Safety and off-label use
Cordis: drug coated stents. Safety and off-label use
Cephalon: Actiq (narcotic lollipop) and Fentora (narcotic lozenge). Inappropriate marketing
Here are the letters that were sent.
WaxmanLilly.pdf
WaxmanAZ.pdf
WaxmanBoston.pdf
WaxmanCordis.pdf
WaxmanCephalon.pdf
The longest letter went to Cephalon over their narcotic products . All the letters are asking for a long list of items to be provided covering clinical trials, audits, presentations, training material, communication to healthcare providers and much more. It will be interesting to watch and see which cooperate and which may refuse to turn over the requested documents. For Cephalon and Actiq it is for data from 1997 to the present; almost 10 years of data.
Technorati Tags: Actiq, AstraZeneca, Boston Scientific, Cephalon, Cordis, Eli Lilly, Fentora, drug coated stents, Seroquel, Waxman, Zyprexa
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
Lilly last week withdrew its application with the European Medicines Agency (EMEA) for Arxxant (ruboxistaurin)
PharmaLive: Eli Lilly Withdraws Its Marketing Authorization Application for Arxxant
The given reason was that they could not respond to the request for the additional information in the required amount of time. Lilly lost an appeal just a few days earlier than this where the FDA upheld thier decision to require additional clinical trials before it would be considered for approval. Lilly said it would take an additional 3-5 years to complete those studies.
My wife is diabetic and has already had some eye problems related to her disease and so I have been following this drug with a personal interest. It will be interesting to see what Lilly will do. Somewhere right now someone is plugging numbers into a spreadsheet to see if it is worthwhile for Lilly to make an additional investment in this drug. Since I have a personal interest in this, I certainly hope so.
Other Resources
Eli Lilly withdraws its marketing authorisation application for ARXXANT (from EMEA website)
FDA rejects Eli Lilly appeal - Pharmaceutical Business Review
Lilly’s Arxxant Hits FDA Snag - Forbes.com (from back in Aug 2006)
Approvable Letter Issued By FDA For Arxxant(R) (ruboxistaurin Mesylate) For Diabetic Retinopathy
Arxxant - Yahoo! Search Results
Arxxant - Google Search
Google Blog Search: Arxxant
Technorati Tags: Arxxant, ruboxistaurin
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
Forbes recently had an article about a vaccine from GlaxoSmithKline (GSK) that may protect against many strains of bird flu.
Vaccine May Treat Many Bird Flu Strains - Forbes.com:
The vaccine measurably increased the levels of antibodies in 400 adults after they were given two shots. THe levels were high enough to give presumed protection against the strain of bird flu it was designed to work against. The more promising result is that it may protect against other strains. Other companies such as Novartis and Sanofi-Aventis has also seen cross-protection in their vaccines. What is interesting is the GSK is using a proprietary adjunct which can increase the number of doses by 10-fold. This would be vital if there were an epidemic.
Technorati Tags: avian flu, bird flu, GlaxoSmithKline, H5N1, Novartis, Sanofi-Aventis, vaccine
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
Back in January, Reuters had this article on the mysterious pain condition referred to as fibromyalgia
Drugs nearing approval for mysterious pain condition | Health | Reuters.com:
The condition is controversial because it is not east to diagnose and there is no test for it. The diagnosis is made based on patient complaints and responses to subjective questions during an exam. It is estimated that the condition may affect as many as 12 million Americans mainly females. I’m not qualified to say wether or not it should be a recognized disease but it is interesting to note that several major pharma companies are looking at this as an area ripe for new drugs to target this. Among the companies actively developing drugs for fibromyalgia are Pfizer, Lilly, Forest Labs and Wyeth. There may be more but these are mentioned in the above article.
Why is big pharma interested in this? Because it could be a $1 billion market by 2014; it is currently fairly small. The first drug could be approved as soon as next year for fibromylagia. Already Cymbalta from Lilly and Lyrica from Pfizer are being used off label to treat fibromylagia. If either of these two could get approved for this additional indication it could be another $ 200-400 million in annual sales annually for them..
The first approach is to test drugs that companies already sell for other diseases to try and see if they work. Longer term, I am sure their is research ongoing to develop new chemical entities (NCEs) specifically for this condition. However, given the lack of basic understanding of the disorder, it must be difficult to find an animal model to do testing in.
Other Resources
National Fibromyalgia Association
National Fibromyalgia Research Association
fibromyalgia - Yahoo! Search Results
fibromyalgia - Google Search
Technorati Tags: Cymbalta, fibromyalgia, Lyrica, Wyeth
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
I somehow didn’t post on this merger from back in early February. Corautus is going to merge with VIA Pharmaceuticals
Corautus to merge with San Francisco company - Atlanta Business Chronicle: :
I’m not familiar with either of these small companies but since I’ve been trying to keep up with M$A activity in the industry I wanted to include it. Corautus Genetics Inc. is a small private company located in
Atlanta GA (hence the reporting in the Atlanta Business Chronicle) focused on cardiovascular and peripheral vascular disease.
VIA Pharmaceuticals is located in San Francisco, CA and also focuses on vascular disease so they seem to be a good fit. I can’t comment on it more than that.
Other Resources
Corautus Genetics and VIA Pharmaceuticals Announce Merger Agreement (official press release)
Corautus Genetics and VIA Pharmaceuticals Announce Merger Agreement: Financial News - Yahoo! Finance
Google Blog Search: corautus “VIA pharmaceuticals”
Technorati Tags: Coratus, VIA Pharmaceuticals
Bookmark it with:
| del.icio.us
| Digg it
| Furl
| Simpy
| Spurl
| My Yahoo!
|
Pages (999999): « First ... « 4 5 [6] 7 8 » ... Last »
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.
By Category
Chemistry, science, and technology for the future.
87 queries. 2.329 seconds
